Home > Publications Database > Patient-derived monoclonal LGI1 autoantibodies elicit seizures, behavioral changes and brain MRI abnormalities in rodent models. > print

001     277509
005     20250320091335.0
024 7 _ |a 10.1016/j.bbi.2025.02.019
|2 doi
024 7 _ |a pmid:39984135
|2 pmid
024 7 _ |a 0889-1591
|2 ISSN
024 7 _ |a 1090-2139
|2 ISSN
037 _ _ |a DZNE-2025-00420
041 _ _ |a English
082 _ _ |a 150
100 1 _ |a Upadhya, Manoj
|b 0
245 _ _ |a Patient-derived monoclonal LGI1 autoantibodies elicit seizures, behavioral changes and brain MRI abnormalities in rodent models.
260 _ _ |a Orlando, Fla. [u.a.]
|c 2025
|b Elsevier
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1742378770_6428
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Limbic encephalitis with leucine-rich glioma inactivated 1 (LGI1) protein autoantibodies is associated with cognitive impairment, psychiatric symptoms, and seizures, including faciobrachial dystonic seizures (FBDS). Patient-derived LGI1-autoantibodies cause isolated symptoms of memory deficits in mice and seizures in rats. Using a multimodal experimental approach, we set out to improve the validity of existing in vivo rodent models to further recapitulate the full clinical syndrome of anti-LGI1 antibody mediated disease.A monoclonal anti-LGI1 antibody (anti-LGI1 mAb) derived from a patient's CSF antibody-secreting cell was infused intracerebroventricularly (ICV) into rats and mice for one or two weeks, respectively. Cellular excitability of CA3 pyramidal neurons was determined in hippocampal slices. Structural changes in mouse brains were explored using MRI. Antibody effects on behavior and brain activity of rats were studied using video-EEG.Anti-LGI1 mAbs augmented the excitability of CA3 pyramidal neurons and elicited convulsive and non-convulsive spontaneous epileptic seizures in mice and rats. Mice displayed a hypoactive and anxious phenotype during behavioral testing. MRI revealed acutely increased hippocampal volume after ICV anti-LGI1 mAb infusion. Video-EEG recordings of juvenile rats uncovered two peaks of seizure frequency during the 7-day antibody infusion period resembling the natural progression of seizures in human anti-LGI1 encephalitis.Our data strongly corroborate and extend our understanding of the direct pathogenic and epileptogenic role of human LGI1 autoantibodies.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
536 _ _ |a 351 - Brain Function (POF4-351)
|0 G:(DE-HGF)POF4-351
|c POF4-351
|f POF IV
|x 1
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a Animal model
|2 Other
650 _ 7 |a Human monoclonal antibody
|2 Other
650 _ 7 |a LGI1
|2 Other
650 _ 7 |a Limbic encephalitis
|2 Other
650 _ 7 |a Seizure
|2 Other
700 1 _ |a Stumpf, Alexander
|b 1
700 1 _ |a O'Brien-Cairney, Jack
|b 2
700 1 _ |a Cordero Gomez, Cesar
|0 P:(DE-2719)9001947
|b 3
|u dzne
700 1 _ |a Döring, Jan Michael
|0 P:(DE-2719)2814277
|b 4
700 1 _ |a Hoffmann, Julius
|0 P:(DE-2719)9001563
|b 5
|u dzne
700 1 _ |a Mueller, Susanne
|b 6
700 1 _ |a Fukata, Yuko
|b 7
700 1 _ |a van Hoof, Scott
|0 P:(DE-2719)2812820
|b 8
|u dzne
700 1 _ |a Dhangar, Divya
|b 9
700 1 _ |a Wilson, Max A
|b 10
700 1 _ |a Atwal, Arunvir
|b 11
700 1 _ |a Rosch, Richard
|b 12
700 1 _ |a Woodhall, Gavin
|b 13
700 1 _ |a Boehm-Sturm, Philipp
|b 14
700 1 _ |a Fukata, Masaki
|b 15
700 1 _ |a Kreye, Jakob
|0 P:(DE-2719)2811468
|b 16
|u dzne
700 1 _ |a Schmitz, Dietmar
|0 P:(DE-2719)2810725
|b 17
|u dzne
700 1 _ |a Wright, Sukhvir K
|b 18
700 1 _ |a Kornau, Hans-Christian
|0 P:(DE-2719)2811900
|b 19
|u dzne
700 1 _ |a Prüss, Harald
|0 P:(DE-2719)2810931
|b 20
|e Last author
|u dzne
773 _ _ |a 10.1016/j.bbi.2025.02.019
|g Vol. 126, p. 342 - 355
|0 PERI:(DE-600)1462491-6
|p 342 - 355
|t Brain, behavior and immunity
|v 126
|y 2025
|x 0889-1591
856 4 _ |u https://pub.dzne.de/record/277509/files/DZNE-2025-00420%20SUP.mp4
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/277509/files/DZNE-2025-00420.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/277509/files/DZNE-2025-00420.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:277509
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 3
|6 P:(DE-2719)9001947
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 4
|6 P:(DE-2719)2814277
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 5
|6 P:(DE-2719)9001563
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 8
|6 P:(DE-2719)2812820
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 16
|6 P:(DE-2719)2811468
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 17
|6 P:(DE-2719)2810725
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 19
|6 P:(DE-2719)2811900
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 20
|6 P:(DE-2719)2810931
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-351
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Brain Function
|x 1
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-19
915 _ _ |a IF >= 15
|0 StatID:(DE-HGF)9915
|2 StatID
|b BRAIN BEHAV IMMUN : 2022
|d 2024-12-19
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b BRAIN BEHAV IMMUN : 2022
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2024-12-19
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-19
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-19
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-19
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2024-12-19
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-19
920 1 _ |0 I:(DE-2719)1810003
|k AG Prüß
|l Autoimmune Encephalopathies
|x 0
920 1 _ |0 I:(DE-2719)1810004
|k AG Schmitz
|l Network Dysfunction
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1810003
980 _ _ |a I:(DE-2719)1810004
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21